BioCentury | Oct 29, 2015
Product R&D

Qureing antibiotic resistance

...T3SS pathway inhibitors targeting Gram-negative bacteria, filed for bankruptcy in June. Debiopharm Group is developing Debio 1452...
BioCentury | Feb 17, 2014
Company News

Affinium, Debiopharm deal

...for structure-guided discovery of fatty acid biosynthesis 1 (FAB1) inhibitors. The assets also include Affinium's AFN-1252...
...the compound has Qualified Infectious Disease Product (QIDP) designation; and AFN-1720 , a prodrug of AFN-1252...
BioCentury | Feb 12, 2014
Company News

Debiopharm acquires Affinium's antibiotic assets

...wind down operations. Financial terms of the deal were not disclosed. The assets include Affinium's AFN-1252...
...the compound has Qualified Infectious Disease Product (QIDP) designation; and AFN-1720 , a prodrug of AFN-1252...
BioCentury | Nov 18, 2013
Clinical News

AFN-1252 regulatory update

...Affinium said FDA granted Qualified Infectious Disease Product (QIDP) designation for AFN-1252 to treat acute bacterial...
...completed Phase II testing in ABSSSI. Affinium Pharmaceuticals Ltd. , Austin, Texas Product: AFN-1252 (formerly API-1252...
BioCentury | Sep 16, 2013
Clinical News

AFN-1720: Phase I started

...single ascending-doses of IV AFN-1720 in healthy volunteers. The compound is a prodrug of Affinium's AFN-1252...
BioCentury | Apr 1, 2013
Clinical News

AFN-1252: Phase IIa data

...trial in 103 patients with ABSSSI due to Staphylococcus showed that twice-daily 200 mg oral AFN-1252...
...vomiting. This year, Affinium plans to conduct Phase I trials evaluating an IV formulation of AFN-1252...
...next steps for the oral formulation. Affinium Pharmaceuticals Ltd. , Austin, Texas Product: AFN-1252 (formerly API-1252...
BioCentury | Aug 13, 2012
Clinical News

AFN-1252: Phase II started

...AFN-1252 twice daily for 5-14 days. Affinium Pharmaceuticals Ltd. , Austin, Texas Product: AFN-1252 (formerly API-1252...
BioCentury | Feb 6, 2012
Clinical News

AFN-1252: Phase II started

...Affinium began an open-label, U.S. and Canadian Phase II trial to evaluate 200 mg oral AFN-1252...
...100 patients with staphylococcal skin infections. Affinium Pharmaceuticals Ltd. , Austin, Texas Product: AFN-1252 (formerly API-1252...
BioCentury | Aug 31, 2011
Financial News

Affinium adds $15M in B round

...SV Life Sciences; Genesis Capital; and Forward Ventures in the round. Affinium's lead compound is AFN-1252...
BioCentury | May 9, 2011
Clinical News

AFN-1252: Phase I data

...U.S. Phase I trial in 32 healthy volunteers showed that 200, 300 and 400 mg AFN-1252...
...daily for 10 days was well tolerated. PK data showed that 300 or 400 mg AFN-1252...
...exceeded levels to treat staphylococcal infection. Affinium Pharmaceuticals Ltd. , Austin, Texas Product: AFN-1252 (formerly API-1252...
Items per page:
1 - 10 of 16